Evidence map›Paper›PMID 38532951›Full record

ArticleOpen forum infectious diseases2024

The Enterics for Global Health (EFGH)

Katia Manzanares Villanueva, Tackeshy Pinedo Vasquez, Pablo Peñataro Yori, Lucero Romaina Cacique, Paul F Garcia Bardales, Wagner V Shapiama Lopez, Fiorella Zegarra Paredes, Karin F Perez, Silvia Rengifo Pinedo, Hermann Silva Delgado and 5 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Shigellosis.Lancet (London, England) · 2025
    Review
  5. Article
  6. Article
  7. Quantifying the Cost ofOpen forum infectious diseases · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Katia Manzanares VillanuevaAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Tackeshy Pinedo VasquezAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Pablo Peñataro YoriDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Lucero Romaina CaciqueAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Paul F Garcia BardalesAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Wagner V Shapiama LopezAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Fiorella Zegarra ParedesAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Karin F PerezAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Silvia Rengifo PinedoAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Hermann Silva DelgadoFacultad de Medicina Humana, Universidad Nacional de la Amazonia Peruana, Iquitos, Loreto, Peru.
Thomas FlynnDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Francesca SchiaffinoDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Josh M ColstonDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Maribel Paredes Paredes OlorteguiAsociación Benéfica Prisma, Unidad de Investigaciones Biomedicas, Iquitos, Loreto, Peru.
Margaret N KosekDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Prisma · PEUniversity of Virginia · USUniversidad Nacional de la Amazonía Peruana · PE

Funding

Global Biothreats Training ProgramT32AI055432 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI CRISS, ALISON K, PETRI, WILLIAM A · 2003 to 2022
$4.0M
Enabling Infectious Disease Research Capacity in the Peruvian AmazonD43TW010913 · FIC · UNIVERSITY OF VIRGINIA · PI Margaret N Kosek, MARIBEL PAREDES OLORTEGUI · 2018 to 2026
$2.8M
Genomic Epidemiology of Campylobacter in Poultry to Enable the Effective Control of Human Campylobacteriosis in a Middle Income CountryK43TW012298 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI Francesca Schiaffino · 2022 to 2026
$811k
The Planetary Child Health Observatory: an interdisciplinary research initiative and web-based dashboard for mapping enteric infectious diseases and their risk factors and interventions in LMICsK01AI168493 · NIAID · UNIVERSITY OF VIRGINIA · PI Josh M Colston · 2023 to 2026
$519k
FIC NIH HHS D43 TW010913FIC NIH HHS K43 TW012298Gates Foundation INV-028721Gates Foundation INV-041730NIAID NIH HHS K01 AI168493NIAID NIH HHS T32 AI055432
6 · The paper itself

Abstract

Background: The Enterics for Global Health (EFGH) Peru site will enroll subjects in a periurban area of the low Amazon rainforest. The political department of Loreto lags behind most of Peru in access to improved sources of water and sanitation, per capita income, children born <2.5 kg, and infant and child mortality. Chronic undernutrition as manifested by linear growth shortfalls is common, but wasting and acute malnutrition are not. Methods: The recruitment of children seeking care for acute diarrheal disease takes place at a geographic cluster of government-based primary care centers in an area where most residents are beneficiaries of free primary healthcare. Results: Rates of diarrheal disease, dysentery, and Conclusions: Immunization has been offered universally against rotavirus in the region since 2009, and in a context where adequate water and sanitation are unlikely to obtain high standards in the near future, control of principal enteropathogens through immunization may be the most feasible way to decrease the high burden of disease in the area in the near future.

Indexed as

AmazondiarrheaLoretoShigellashigellosis

Identifiers

PMID38532951
PMCPMC10962730
OpenAlexW4393166973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.